NCT03801798View on ClinicalTrials.gov

A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Hepatitis B
Interventions
DRUG

GC1102

NAs antivirals+GC1102 180,000 IU

OTHER

GC1102 Placebo

NAs antivirals+GC1102 Placebo

Trial Locations (1)

Unknown

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Green Cross Corporation

INDUSTRY